Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arjen Scholten is active.

Publication


Featured researches published by Arjen Scholten.


Journal of the American Chemical Society | 2013

On Terminal Alkynes That Can React with Active-Site Cysteine Nucleophiles in Proteases

Reggy Ekkebus; Sander I. van Kasteren; Yogesh Kulathu; Arjen Scholten; Ilana Berlin; Paul P. Geurink; Annemieke de Jong; Soenita S. Goerdayal; Jacques Neefjes; Albert J. R. Heck; David Komander; Huib Ovaa

Active-site directed probes are powerful in studies of enzymatic function. We report an active-site directed probe based on a warhead so far considered unreactive. By replacing the C-terminal carboxylate of ubiquitin (Ub) with an alkyne functionality, a selective reaction with the active-site cysteine residue of de-ubiquitinating enzymes was observed. The resulting product was shown to be a quaternary vinyl thioether, as determined by X-ray crystallography. Proteomic analysis of proteins bound to an immobilized Ub alkyne probe confirmed the selectivity toward de-ubiquitinating enzymes. The observed reactivity is not just restricted to propargylated Ub, as highlighted by the selective reaction between caspase-1 (interleukin converting enzyme) and a propargylated peptide derived from IL-1β, a caspase-1 substrate.


Drug Discovery Today | 2009

Revealing promiscuous drug–target interactions by chemical proteomics

Marcus Bantscheff; Arjen Scholten; Albert J. R. Heck

The (poly-)pharmacological activities of a drug can only be understood if its interactions with cellular components are comprehensively characterized. Mass spectrometry-based chemical proteomics approaches have recently emerged as powerful tools for the characterization of drug-target interactions in samples from cell lines and tissues. At the same time, off-target activities can be identified. This information can contribute toward optimization of candidate drug molecules and reduction of side effects. In this review, we describe recent advances in chemical proteomics and outline potential applications in drug discovery.


Nature Methods | 2012

Protease bias in absolute protein quantitation

Mao Peng; Nadia Taouatas; Salvatore Cappadona; Bas van Breukelen; Shabaz Mohammed; Arjen Scholten; Albert J. R. Heck

A systematic shortcoming of high-throughput sequence analyses is that they usually neglect the contribution of mtDNA to organismal genotype and phenotype. The coordinated expression of the mitochondrial and nuclear genomes is essential for eukaryotic cells and organisms to function5. Moreover, mitochondrial dysfunctions have pleiotropic effects in multicellular organisms and are associated with a large spectrum of metabolic and neuromuscular disorders, aging and cancer6. Applying our simple but effective method to WES data from diverse cytotypes representing a large variety of physiological and disease conditions could provide valuable insights into pathological effects of mutations and structural variations of mtDNA. Indeed, the integration of mtDNA with nuclear exome data may contribute to a better understanding of nuclear-mitochondrial genome interplay in both healthy and pathological conditions.


Analytical and Bioanalytical Chemistry | 2012

Applications of stable isotope dimethyl labeling in quantitative proteomics

Duangnapa Kovanich; Salvatore Cappadona; Reinout Raijmakers; Shabaz Mohammed; Arjen Scholten; Albert J. R. Heck

Mass spectrometry has proven to be an indispensable tool for protein identification, characterization, and quantification. Among the possible methods in quantitative proteomics, stable isotope labeling by using reductive dimethylation has emerged as a cost-effective, simple, but powerful method able to compete at any level with the present alternatives. In this review, we briefly introduce experimental and software methods for proteome analysis using dimethyl labeling and provide a comprehensive overview of reported applications in the analysis of (1) differential protein expression, (2) posttranslational modifications, and (3) protein interactions.


Arteriosclerosis, Thrombosis, and Vascular Biology | 2013

High precision platelet releasate definition by quantitative reversed protein profiling--brief report.

Patrick Wijten; Thijs C. van Holten; Liy Liy Woo; Onno B. Bleijerveld; Mark Roest; Albert J. R. Heck; Arjen Scholten

Objective—Platelet activation and subsequent protein release play an important role in healthy hemostasis and inflammatory responses, yet the identity and quantity of proteins in the platelet releasate are still debated. Here, we present a reversed releasate proteomics approach to determine unambiguously and quantitatively proteins released from activated platelets. Approach and Results—Isolated platelets were mock and fully stimulated after which the released proteins in the supernatant were removed. Using high-end proteomics technology (2D chromatography, stable isotope labeling, electron transfer dissociation, and high collision dissociation fragmentation) allowed us to quantitatively discriminate the released proteins from uncontrolled lysis products. Monitoring the copy numbers of ≈4500 platelet proteins, we observed that after stimulation via thrombin and collagen, only 124 (<3%) proteins were significantly released (P<0.05). The released proteins span a concentration range of ≥5 orders, as confirmed by ELISA. The released proteins were highly enriched in secretion tags and contained all known factors at high concentrations (>100 ng/mL, eg, thrombospondin, von Willebrand factor, and platelet factor 4). Interestingly, in the lower concentration range of the releasate many novel factors were identified. Conclusions—Our reversed releasate dataset forms the first unambiguous, in depth repository for molecular factors released by platelets.


Journal of Biological Chemistry | 2012

A Small Novel A-Kinase Anchoring Protein (AKAP) That Localizes Specifically Protein Kinase A-Regulatory Subunit I (PKA-RI) to the Plasma Membrane

Pepijn P. Burgers; Yuliang Ma; Luigi Margarucci; Mason R. Mackey; Marcel A.G. van der Heyden; Mark H. Ellisman; Arjen Scholten; Susan S. Taylor; Albert J. R. Heck

Background: AKAPs tethering the type I regulatory subunit of cAMP-dependent kinase (PKA-RI) have only been marginally described. Results: Here a novel small AKAP (smAKAP) is identified and characterized as a PKA-RI-specific AKAP. Conclusion: smAKAP is a novel AKAP that localizes PKA-RI specifically to the plasma membrane. Significance: PKA-RI is specifically localized through a novel AKAP. Protein kinase A-anchoring proteins (AKAPs) provide spatio-temporal specificity for the omnipotent cAMP-dependent protein kinase (PKA) via high affinity interactions with PKA regulatory subunits (PKA-RI, RII). Many PKA-RII-AKAP complexes are heavily tethered to cellular substructures, whereas PKA-RI-AKAP complexes have remained largely undiscovered. Here, using a cAMP affinity-based chemical proteomics strategy in human heart and platelets, we uncovered a novel, ubiquitously expressed AKAP, termed small membrane (sm)AKAP due to its specific localization at the plasma membrane via potential myristoylation/palmitoylation anchors. In vitro binding studies revealed specificity of smAKAP for PKA-RI (Kd = 7 nm) over PKA-RII (Kd = 53 nm) subunits, co-expression of smAKAP with the four PKA R subunits revealed an even more exclusive specificity of smAKAP for PKA-RIα/β in the cellular context. Applying the singlet oxygen-generating electron microscopy probe miniSOG indicated that smAKAP is tethered to the plasma membrane and is particularly dense at cell-cell junctions and within filopodia. Our preliminary functional characterization of smAKAP provides evidence that, like PKA-RII, PKA-RI can be tightly tethered by a novel repertoire of AKAPs, providing a new perspective on spatio-temporal control of cAMP signaling.


Arteriosclerosis, Thrombosis, and Vascular Biology | 2013

High Precision Platelet Releasate Definition by Quantitative Reversed Protein Profiling

Patrick Wijten; Thijs C. van Holten; Liy Liy Woo; Onno B. Bleijerveld; Mark Roest; Albert J. R. Heck; Arjen Scholten

Objective—Platelet activation and subsequent protein release play an important role in healthy hemostasis and inflammatory responses, yet the identity and quantity of proteins in the platelet releasate are still debated. Here, we present a reversed releasate proteomics approach to determine unambiguously and quantitatively proteins released from activated platelets. Approach and Results—Isolated platelets were mock and fully stimulated after which the released proteins in the supernatant were removed. Using high-end proteomics technology (2D chromatography, stable isotope labeling, electron transfer dissociation, and high collision dissociation fragmentation) allowed us to quantitatively discriminate the released proteins from uncontrolled lysis products. Monitoring the copy numbers of ≈4500 platelet proteins, we observed that after stimulation via thrombin and collagen, only 124 (<3%) proteins were significantly released (P<0.05). The released proteins span a concentration range of ≥5 orders, as confirmed by ELISA. The released proteins were highly enriched in secretion tags and contained all known factors at high concentrations (>100 ng/mL, eg, thrombospondin, von Willebrand factor, and platelet factor 4). Interestingly, in the lower concentration range of the releasate many novel factors were identified. Conclusions—Our reversed releasate dataset forms the first unambiguous, in depth repository for molecular factors released by platelets.


Molecular & Cellular Proteomics | 2009

Selectivity in Enrichment of cAMP-dependent Protein Kinase Regulatory Subunits Type I and Type II and Their Interactors Using Modified cAMP Affinity Resins

Thin Thin Aye; Shabaz Mohammed; Henk van den Toorn; Toon A.B. van Veen; Marcel A.G. van der Heyden; Arjen Scholten; Albert J. R. Heck

cAMP regulates cellular functions primarily by activating PKA. The involvement of PKAs in various signaling pathways occurring simultaneously in different cellular compartments necessitates stringent spatial and temporal regulation. This specificity is largely achieved by binding of PKA to protein scaffolds, whereby a distinct group of proteins called A kinase anchoring proteins (AKAPs) play a dominant role. AKAPs are a diverse family of proteins that all bind via a small PKA binding domain to the regulatory subunits of PKA. The binding affinities between PKA and several AKAPs can be different for different isoforms of the regulatory subunits of PKA. Here we employ a combination of affinity chromatography and mass spectrometry-based quantitative proteomics to investigate specificity in PKA-AKAP interactions. Three different immobilized cAMP analogs were used to enrich for PKA and its interacting proteins from several systems; HEK293 and RCC10 cells and rat lung and testis tissues. Stable isotope labeling was used to confidently identify and differentially quantify target proteins and their preferential binding affinity for the three different cAMP analogs. We were able to enrich all four isoforms of the regulatory subunits of PKA and concomitantly identify more than 10 AKAPs. A selective enrichment of the PKA RI isoforms could be achieved; which allowed us to unravel which AKAPs bind preferentially to the RI or RII regulatory domains of PKA. Of the twelve AKAPs detected, seven preferentially bound to RII, whereas the remaining five displayed at least dual specificity with a potential preference for RI. For some of these AKAPs our data provide the first insights into their specificity.


Cardiovascular Research | 2014

Quantitative proteomics analysis reveals similar release profiles following specific PAR-1 or PAR-4 stimulation of platelets

Thijs C. van Holten; Onno B. Bleijerveld; Patrick Wijten; Philip G. de Groot; Albert J. R. Heck; Arjan D. Barendrecht; Tesy H. Merkx; Arjen Scholten; Mark Roest

AIMS Platelets are a natural source of growth factors, cytokines and chemokines, that regulate angiogenesis and inflammation. It has been suggested that differential release of pro- and anti-angiogenic growth factors from platelet α-granules by protease-activated receptors (PAR) 1 and 4 may be important for the regulation of angiogenesis. We aimed to compare the releasates of unstimulated platelets with PAR-1- and PAR-4-stimulated platelets. METHODS AND RESULTS The release of β-thromboglobulin, platelet factor (PF)-4, thrombospondin, platelet-derived growth factor (PDGF)-A/B, regulated and normal T-cell expressed and secreted (RANTES/CCL5), endostatin, CXCL12, and vascular endothelial growth factor (VEGF) was measured with enzyme-linked immunosorbent assay (ELISA). Mass spectrometry (MS)-based quantitative proteomics identified 93 proteins from platelets stimulated with PAR-1 and PAR-4. A strong correlation between the factors released after either stimulus was observed (Spearmans r 0.94, P < 0.001). Analysis with ELISA showed that stimulation with PAR-1 or PAR-4 lead to non-differential release of β-thromboglobulin, PF-4, thrombospondin, PDGF-A/B, RANTES/CCL5, endostatin, CXCL12, and VEGF. Release of thrombospondin was slightly lower after PAR-1 stimulation (7.2 μg/mL), compared with PAR-4 induced release (9.8 μg/mL; P < 0.05). CONCLUSIONS Both ELISA on established α-granule proteins and MS-based quantitative proteomics showed that the most abundant α-granule proteins are released in similar quantities from platelets after stimulation with either PAR-1 or PAR-4. Our findings provide evidence against the hypothesis that PAR-1 and PAR-4 stimulation of platelets trigger differential release of alpha-granule, but further studies are needed to draw conclusions for physiological conditions.


Journal of Proteome Research | 2014

Identification of Enriched PTM Crosstalk Motifs from Large-Scale Experimental Data Sets

Mao Peng; Arjen Scholten; Albert J. R. Heck; Bas van Breukelen

Post-translational modifications (PTMs) play an important role in the regulation of protein function. Mass spectrometry based proteomics experiments nowadays identify tens of thousands of PTMs in a single experiment. A wealth of data has therefore become publically available. Evidently the biological function of each PTM is the key question to be addressed; however, such analyses focus primarily on single PTM events. This ignores the fact that PTMs may act in concert in the regulation of protein function, a process termed PTM crosstalk. Relatively little is known on the frequency and functional relevance of crosstalk between PTM sites. In a bioinformatics approach, we extracted PTMs occurring in proximity in the protein sequence from publically available databases. These PTMs and their flanking sequences were subjected to stringent motif searches, including a scoring for evolutionary conservation. Our unprejudiced approach was able to detect a respectable set of motifs, of which about half were described previously. Among these we could add many new proteins harboring these motifs. We extracted also several novel motifs, which through their widespread appearance and high conservation may pinpoint at previously nonannotated concerted PTM actions. By employing network analyses on these proteins, we propose putative functional roles for these novel motifs with two PTM sites in close proximity.

Collaboration


Dive into the Arjen Scholten's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Onno B. Bleijerveld

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marc A. Vos

University of Michigan

View shared research outputs
Researchain Logo
Decentralizing Knowledge